Dept of Clinical Neuroscience, Karolinska Inst
Stockholm, 14176, Sweden
NCT Number: NCT00310934
The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy, where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 4
Stockholm, 14176, Sweden
The objective of this study is to compare optimally given methadone maintenance treatment (MMT) for heroin dependence with a novel, sequential strategy (STEP), where patients are offered buprenorphine as first line treatment, allowed dose adjustments as needed, and switched to methadone if the maximal dose of buprenorphine is insufficient.
For this purpose, 96 subjects at two centers (Uppsala and Stockholm) are randomized to MMT or STEP and followed for 6 months. Retention in treatment is the primary outcome. Secondary outcomes in completers are proportion urine samples free of illicit opiates on app. twice weekly sampling, and problem severity as measured by a semistructured interview, the Addiction Severity Index (ASI) at baseline and after 3 and 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Karolinska University Hospital
Other
Graded Strategy for Pharmacological Treatment of Heroin Dependence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02774954
Amphetamine Dependence, Amphetamine-Related Disorders
Los Angeles, California, United States
View Trial DetailsNCT02324725
Behavior, Behavior, Addictive
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT01999946
Chemically-Induced Disorders, Heroin Dependence
New York, United States
View Trial DetailsNCT03015246
Chemically-Induced Disorders, Heroin Dependence
Overland Park, Kansas, United States
View Trial Details